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Abstract
Background: Alkaptonuria (AKU) is an ultra-rare autosomal recessive disease caused by a mutation in the
homogentisate 1,2-dioxygenase (HGD) gene. One of the main obstacles in studying AKU, and other ultra-rare
diseases, is the lack of a standardized methodology to assess disease severity or response to treatment. Quality of
Life scores (QoL) are a reliable way to monitor patients’ clinical condition and health status. QoL scores allow to
monitor the evolution of diseases and assess the suitability of treatments by taking into account patients’
symptoms, general health status and care satisfaction. However, more comprehensive tools to study a complex and
multi-systemic disease like AKU are needed. In this study, a Machine Learning (ML) approach was implemented
with the aim to perform a prediction of QoL scores based on clinical data deposited in the ApreciseKUre, an AKU-
dedicated database.
Method: Data derived from 129 AKU patients have been firstly examined through a preliminary statistical analysis
(Pearson correlation coefficient) to measure the linear correlation between 11 QoL scores. The variable importance
in QoL scores prediction of 110 ApreciseKUre biomarkers has been then calculated using XGBoost, with K-nearest
neighbours algorithm (k-NN) approach. Due to the limited number of data available, this model has been validated
using surrogate data analysis.
Results: We identified a direct correlation of 6 (age, Serum Amyloid A, Chitotriosidase, Advanced Oxidation Protein
Products, S-thiolated proteins and Body Mass Index) out of 110 biomarkers with the QoL health status, in particular
with the KOOS (Knee injury and Osteoarthritis Outcome Score) symptoms (Relative Absolute Error (RAE) 0.25). The
error distribution of surrogate-model (RAE 0.38) was unequivocally higher than the true-model one (RAE of 0.25),
confirming the consistency of our dataset. Our data showed that inflammation, oxidative stress, amyloidosis and
lifestyle of patients correlates with the QoL scores for physical status, while no correlation between the biomarkers
and patients’ mental health was present (RAE 1.1).
Conclusions: This proof of principle study for rare diseases confirms the importance of database, allowing data
management and analysis, which can be used to predict more effective treatments.
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Background
Alkaptonuria (AKU) was described by Garrod in 1908 [1]
as the first disorder to conform with the principles of Men-
delian recessive inheritance. The estimated incidence of
AKU is 1 case in 250.000–1.000.000 births in most ethnic
groups [2], with about 950 patients reported in 61 countries
[3]. AKU patients carry homozygous or compound hetero-
zygous mutations of the HGD gene leading to a deficiency
of the enzyme homogentisate 1,2-dioxygenase (HGD),
which is involved in the catabolic pathway of tyrosine [4, 5].
Such dysfunction causes accumulation of homogentisic acid
(HGA). Most of HGA is excreted through the urine, result-
ing in the characteristic darkening-upon-standing, but
smaller HGA amounts can also accumulate in connective
tissues, where HGA polymerizes forming a dark brown
melanin-like pigment (ochronotic pigment). Ochronosis af-
fects skin, sclera and ears (presenting with blue-black dis-
colouration), spine and joints (causing a dramatic
degeneration and chronic inflammation), heart valves (lead-
ing to stenosis), and kidneys (where stones may develop)
[2]. Ochronosis is also the main cause of arthropathy early
onset, severely reducing patients’ quality of life and causing
pain and deficiency in locomotion [6]. HGA has also been
found to trigger oxidative stress in AKU [7–10]. Since oxi-
dized lipids are cytotoxic and responsible for initiating in-
flammatory reactions, a strict correlation between
cytotoxicity of the ochronotic pigment and inflammation
has be suggested [11]. It has been shown that useful bio-
markers for oxidative stress and inflammation in AKU are
the Advanced Oxidation Protein Products (AOPP), the
products of the oxidation reaction between plasma proteins
and oxidizing agents [12–14].
Recent studies have classified AKU as a secondary
amyloidosis [11, 15–18], characterised by deposition of
serum amyloid A (SAA) fibers, which in its soluble form
is a circulating protein produced during chronic inflam-
matory processes. Studies on AKU patients’ samples
(cartilage, salivary glands, chondrocytes and synovio-
cytes) showed that ochronotic pigment and amyloid fi-
bers share the same location, confirming that SAA is
associated with the ochronotic pigment derived from
HGA [15]. Under normal conditions SAA is found at
low concentrations in plasma (4–6mg/L), while inflam-
matory stimulus or tissue damage increase SAA plasma
levels 100–1000 times [19], making SAA a sensitive bio-
marker of inflammation [19]. On top of SAA deposition,
SAA plasma level have also been reported to be high in
AKU patients ([11, 12, 15–18, 20].
Chitotriosidase (CHIT1) is a chitinase mainly expressed
in the differentiated and polarized macrophages [21].
CHIT1 serum concentration correlates with the progres-
sion or the severity of several diseases (sarcoidosis, rheuma-
toid arthritis, ankylosing spondylitis, uveitis, idiopathic
pulmonary fibrosis, scleroderma-associated interstitial lung
diseases, and chronic obstructive lung diseases), suggesting
a potential use of CHIT1 as an AKU biomarker [20, 21].
The major obstacle in carrying out clinical research on
AKU is the lack of a standardized methodology to assess
disease severity and response to treatment [22], which is
complicated by the fact that AKU symptoms differ from
an individual to another and no correlation between spe-
cific HGD mutations and disease severity has been ob-
served so far [5, 23]. A reliable way to monitor patients’
clinical condition and overall health status is the use in
clinical practice and research of measures of quality of life
(QoL) [20, 24]. QoL allows to observe the evolution of dis-
eases from acute to chronic, and to assess the suitability of
the therapeutic interventions considering patients’ symp-
toms, general health status and care satisfaction [24].
Our previous studies showed that, in a rare and multisys-
temic disease like AKU, QoL scores help to identify health
needs and to evaluate the impact of disease [20, 25], sug-
gesting the presence of a correlation between QoL and the
clinical data deposited in the ApreciseKUre database, which
could be instrumental in shading light on AKU complexity.
Here we have developed a machine learning application
that perform a prediction of the QoL scores based on clin-
ical data deposited in the ApreciseKUre. We believe this ap-
proach can be turned into a best practice model also for
other rare diseases and can be useful for overcoming the
obstacles in small dataset management and analysis.
Materials and methods
Patient data
The ApreciseKUre contains data from 203 patients, but only
129 have a complete and comprehensive set of information,
which have been used in this study [26–28]. ApreciseKUre
contains information about biomarkers and replies to ques-
tionnaires (for a full description of data deposited in Apreci-
seKUre see [20]. Patients data are classified according with
11 QoL scores: (i) physical health score, (ii) mental health
score, (iii) AKU Severity Score Index (AKUSSI) joint pain,
(iv) AKUSSI spinal pain, (v) Knee injury and Osteoarthritis
Outcome Score (KOOS) pain, (vi) KOOS symptoms, (vii)
KOOS daily living, (viii) KOOS sport, (ix) KOOS QOL, (x)
Health Assessment Questionnaire Disability Index (HAQ-
DI) and (xi) global pain visual analog scale (hapVAS). (for
more details see Additional file 1).
Statistical analysis and machine learning
– Preliminary statistical analysis
The input data were firstly examined through a pre-
liminary statistical analysis. A correlation matrix based
on Pearson correlation coefficient was calculated to
measure the linear correlation between QoL scores:
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where σxy is the covariance of the two variables x and y,
σx and σy are the variances of x and y, respectively, and
μx and μy are the mean values.
Application of different ML algorithms
Machine learning (ML) is an algorithm-based novel
modeling technique that has been introduced recently to
select key behavior features (biomarkers) and predict
risk levels [29]. ML methods are more precise and ac-
curate in terms of prediction abilities compared with
traditional statistical methods, because complex inter-
variable interactions are taken into account in ML only
[30]. There are several key steps of the machine
learning-based classification model: data preprocessing,
feature selection, algorithm selection and model evalu-
ation. Our workflow is described in Fig. 1.
In this study, to select the most representative predic-
tors (among biomarkers included in ApreciseKUre) for
QoL scores we have applied Extreme Gradient Boosting
(XGBoost). It is a key algorithm in the processes of clus-
tering evaluation, resampling evaluation, feature selec-
tion and prediction, [31] able to calculate variable
importance defined as the statistical significance of each
variable with respect to its effect on the generated model
[32]. Starting from selected biomarkers, QoL score pre-
diction is then evaluated comparing the performance of
three other different ML techniques: (i) Linear Regres-
sion [33], (ii) Neural networks [34], and (iii) K-nearest
neighbours algorithm (k-NN) [35].). Finally, we applied a
surrogate data method [36].
Results
QoL scores statistical correlation
In the present study, a machine learning algorithm was
implemented with the aim to perform a prediction of
QoL scores based on 129 patients’ clinical data deposited
in the ApreciseKUre database [26, 27]. QoL scores were
firstly examined through a preliminary statistical analysis
in order to evaluate the degree of correlation among
pairs of variables (Fig. 2).
It is interesting to notice the presence of correlation
among AKUSSI, KOOS and HAQ scores. Specifically,
KOOS pain, KOOS symptoms, KOOS daily living and
KOOS sport have a high correlation with AKUSSI joint
pain and spinal pain, and with hapVAS and HAQ-DI.
Differently, the mental health score correlation with all
the other QoL scores is not statistically significant (be-
tween − 0.3 and 0.3). Taken together, these data suggest
that the mental health score, the only one assessing the
psychological status of the patient, is independent from
other QoL scores linked to the individual’s physical sta-
tus. Surprisingly, this finding shows that the patients’
psychological experience, based on the evaluation of
levels of anxiety and depression, is not directly related
with their actual physical and clinical status.
AKU biomarkers selection using XGBoost
Selection of the most representative predictors for QoL
scores was performed by Extreme Gradient Boosting.
XGBoost reveals that the most statistically significant
variables among 110 biomarkers included in Aprecise-
KUre [27] are: age, SAA, CHIT1, AOPP, RSSP, BMI.
Variable importance scores of the above mentioned six
best biomarkers, with respect to every QoL score, are re-
ported in Fig. 3.
ML algorithm selection
Based on these preliminary analyses, different ML
models (Linear Regression, Neural networks and k-NN)
were implemented to improve the correlation analysis of
biomarkers and QoL score. The ML models were com-
pared based on RAE (Relative Absolute Error) indicator
(Table 1) and R2 score (Coefficient of determination):
As such, k-NN resulted to be the most accurate algo-
rithm to predict QoL scores. Therefore, we performed a
Fig. 1 Machine learning framework. A 4-steps workflow of the machine learning-based classification model
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k-NN on each of the 11 QoL scores and KOOS symp-
toms score showed the most accurate prediction (lowest
RAE: 0.25) (Fig. 4). Conversely, mental health scores
might not be predicted with a sufficient accuracy (high-
est RAE: 1.1), indicating limited or no connection with
age, SAA, CHIT1, AOPP, RSSP, BMI values, which is in
line with our preliminary statistical analysis.
Differently from other scores (AKUSSI, KOSS, HAQ,
hapVAS), mental health score is measured across eight
domains (vitality, physical functioning, bodily pain, gen-
eral health perception, physical role functioning, social
functioning, emotional role functioning, mental health),
thus it is not unexpected that there is not a correlation
with age and other AKU biomarkers. This observation,
in line with [20], confirms a not infrequent disability
paradox in inherited/chronic disease, underlying the
difference between the physical and mental impact on
disease severity, which may underestimate overall men-
tal state.
The obtained results demonstrated the power of ML
techniques in extrapolating information from a bio-
markers dataset to make predictions of QoL scores.
ML, with their remarkable ability to derive meaning
from complicated or imprecise data, can be used to ex-
tract patterns and detect trends that are too complex to
be noticed by either humans or other computer
Fig. 2 Correlation matrix of health survey questionnaires. In this correlation matrix all QoL scores are correlated to each other. In black statistically
significant inverse correlation, in light-pink statistically significant direct correlation, in red or purple not statistically significant correlations
Fig. 3 Variable importance Xgboost for each QoL score. In the matrix are reported all the most representative indicators (X axes) with respect to
Qol scores (Y axes) for scores prediction with their corresponding variable importance. Color scale goes from the lower value (in black) to highest
value (light pink)
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techniques. For instance, in Fig. 3, age, SAA, CHIT1,
AOPP, RSSP, BMI related to AKUSSI spinal pain and
AKUSSI joint pain scores assumed the highest variable
importance, suggesting the hypothesis they would have
been the best QoL indicators. However, as shown in
Fig. 4, AKUSSI spinal score and AKUSSI joint pain
RAE for k-NN prediction resulted to be higher in com-
parison with KOOS symptom. Additionally, HAQ hap-
VAS and HAQ-DI showed high RAE despite the
biomarkers variable importance is not different from
KOOS symptom score. In view of this, based on the k-
NN prediction, KOOS symptoms can be considered as
a useful guide for better understanding symptoms and
difficulties experienced by patients.
In conclusion, a k-NN based on the combination of
parameters like age, SAA, CHIT1, AOPP, RSSP and
BMI was able to predict with low RAE the value of
KOOS symptoms. Taken singularly these features are
not predictive and it is already well known that parame-
ters like age, SAA, CHIT1 are linked with disease sever-
ity. The innovative finding of the present work is that,
for the first time, we have found an ensemble of mul-
tiple complementary features (SAA, CHIT1, AOPP,
RSSP, related with inflammation, oxidative stress, amyl-
oidosis; age and BMI, linked with lifestyle) whose com-
bination produce better k-NN prediction results than
any single one.
Validating ML models using surrogate data
Small dataset conditions and the associated random ef-
fects make validation of ML models a challenging task.
For these reasons, to validate the obtained model, we ap-
plied a surrogate data method, which has been previ-
ously shown to be the most suitable method for small
dataset [36]. In this approach, the surrogate data were
generated from random numbers able to mimic the dis-
tribution of the original dataset independently for each
component of the input. They statistically resemble the
original data in terms of their mean, standard deviation
and range, but they do not maintain the complex rela-
tionships between the variables of the real dataset
(Table 2).
Therefore, real-data models are expected to perform
significantly better than the surrogate data models [36].
The same k-NN algorithm was applied to both datasets,
which were randomly split into 80–20% for, respectively,
the training and test sets. Each model was trained and
validated on 1000 different runs, each using a different
training sets, selecting a 10% of the training set to valid-
ate the model. The performances of the model, in terms
of RAE and R2 score, were calculated as the average over
the runs.
The models trained on our real biochemical and clin-
ical dataset achieve an increase in the average of predict-
ive performance than analogous models trained on the
surrogate controls. Indeed, the error distribution of
surrogate-model (RAE 0.38) was unequivocally higher
than the true-model one (RAE of 0.25) confirming the
consistency of our dataset. Thus, it is possible to con-
clude that the obtained predictive method is not biased
or resulting from an overfitting of the model on a small-
sized dataset (Fig. 5). This framework allowed ML algo-
rithms to successfully predict clinical and QoL scores
outcomes despite small datasets.
Table 1 ML algorithm performance comparison
Model RAE R2
Linear Regression 0.34 0.87
Neural networks 0.28 0.91
k-NN 0.25 0.94
Comparison based on RAE and R2 score among different ML models. K-NN
resulted to have the lowest RAE, thus the best performance
Fig. 4 Performance for each QoL Score. Representation of model accuracy (RAE) for each QoL score, scale from the lower value (in light green) to
highest value (blue)
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Discussion
The limited number of AKU patients spread around the
world represent a major obstacle for generating a stan-
dardized strategy to assess disease stage and progression.
While several biomarkers for AKU have been identified,
a clear connection between biomarkers levels and dis-
ease severity (QoL score) is still missing. Here, we imple-
mented an ML method from which QoL of AKU
patients can be predicted based on age, oxidative stress
(AOPP and RSSP), amyloidosis (SAA) inflammation
(CHIT1) biomarkers and BMI, while HGA appears to be
extremely variable and unrelated with disease severity.
An intricate and complex pattern of oxidative stress,
amyloidosis and inflammation is evidently the main im-
portant indicator of patients’ health status.
Moreover, QoL scores worsen progressively with the
age. Aging is associated to decrease antioxidant defenses
(for instance the age-related decline in plasma glutathi-
one (GSH) and low molecular weight thiols) and in-
crease ROS production, allowing oxidatively damaged
macromolecules to accumulate [37]. AKU subjects
undergo a significant decrease in serum free protein
thiols and a significant increase in low molecular weight
mixed-protein thiols with aging [38].
Our ML model suggested that KOOS indicators could
be used to better understanding symptoms and difficul-
ties experienced by AKU patients.
KOOS is a valid, reliable and responsive tool to evalu-
ate both short-term and long-term consequences of knee
injury and primary OA. It is a patient-reported outcome
measurement, developed to assess the opinion of pa-
tients about their knees and associated problems, and it
is routinely used for follow-up evaluations [39]. Multiple
studies in patients with knee injury and knee OA report
that the KOOS demonstrates expected convergent and
divergent construct validity, with the KOOS more
strongly correlated with subscales of the ShortForm- 36
(SF-36) that measure similar constructs [40]. This is the
reason why KOOS prediction could be potentially useful
to assess consequences of primary OA, to evaluate
changes from week to week induced by treatment (medi-
cation, surgery, physical therapy) or over the years due
to a primary knee injury, posttraumatic OA or primary
OA [39], to identify the main important prognostic bio-
markers of AKU, to help the clarification of physiopath-
ological mechanisms of AKU and ochronosis, and to
assess the efficacy of future pharmacological treatments.
Similarly, AOPP and RSSP, indicators of oxidative
stress and inflammation, have shown to influence the k-
NN model. This is not surprising since AKU patients
undergo a significant increase in RSSP with aging [38].
Such a trend suggests that progression of AKU symp-
toms could be related to impaired anti-oxidant status
[10]. HGA induces a significant oxidation of a number
of serum and chondrocyte proteins. Further investiga-
tions allowed highlighting how HGA-induced proteome
alteration, lipid peroxidation, thiol depletion, and amyl-
oid production could contribute to oxidative stress gen-
eration and protein oxidation in AKU [7]. Furthermore,
this is in line with our findings that SAA can be consid-
ered as an AKU biomarker for amyloidosis [15]. In fact,
a chronic inflammatory status paralleled by inadequate
antioxidant defenses is known to promote the aberrant
production of amyloidogenic proteins, ultimately leading
to secondary amyloid deposition [7]. SAA-amyloidosis
Table 2 Correlation matrix of original and surrogate dataset
ORIGINAL Pearson correlation coefficient
Variables SAA CHIT1 AOPP RSSP age BMI
SAA 1.00 −0.01 − 0.01 0.15 0.02 0.23
CHIT1 −0.01 1.00 0.00 0.28 0.40* −0.01
AOPP −0.01 0.00 1.00 0.06 0.09 0.17
RSSP 0.15 0.28 0.06 1.00 0.38* 0.09
Age 0.02 0.40* 0.09 0.38* 1.00 0.14
BMI 0.23 −0.01 0.17 0.09 0.14 1.00
p-value
Variables SAA CHIT1 AOPP RSSP age BMI
SAA 0.00 0.56 1.00 0.11 0.57 0.01
CHIT1 0.56 0.00 0.87 0.00 0.00 0.86
AOPP 1.00 0.87 0.00 0.69 0.45 0.10
RSSP 0.11 0.00 0.69 0.00 0.00 0.59
Age 0.57 0.00 0.45 0.00 0.00 0.28
BMI 0.01 0.86 0.10 0.59 0.28 0.00
SURROGATE Pearson correlation coefficient
Variables SAA CHIT1 AOPP RSSP age BMI
SAA 1.00 −0.16 0.02 0.22 −0.02 −0.16
CHIT1 −0.16 1.00 −0.03 −0.06 −0.08 0.06
AOPP 0.02 −0.03 1.00 −0.12 0.06 −0.01
RSSP 0.22 −0.06 −0.12 1.00 −0.18 0.09
Age −0.02 −0.08 0.06 −0.18 1.00 −0.10
BMI −0.16 0.06 −0.01 0.09 −0.10 1.00
p-value
Variables SAA CHIT1 AOPP RSSP age BMI
SAA 0.00 0.72 1.00 0.23 0.57 0.10
CHIT1 0.72 0.00 0.88 0.02 0.00 1.00
AOPP 1.00 0.88 0.00 0.66 0.61 0.20
RSSP 0.23 0.02 0.66 0.00 0.02 0.58
Age 0.57 0.00 0.61 0.02 0.00 0.28
BMI 0.10 1.00 0.20 0.58 0.28 0.00
The first table shows the Pearson correlations coefficients and the p-values of
our original dataset, the second table shows the Pearson correlations
coefficients and the p-values of surrogate dataset
*indicates statistically significant values
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colocalizes with ochronotic pigment as well as with tis-
sue calcification, lipid oxidation, macrophages infiltra-
tion, cell death, and tissue degeneration [11, 16, 17].
One of the most striking results is that, differentially
from the physical QoL scores based on bodily pain scales
and general factor of physical health, mental health sta-
tus is not predictable by k-NN using the biomarkers
listed above. It is measured across eight domains: vitality,
physical functioning, bodily pain, general health percep-
tion, physical role functioning, social functioning, emo-
tional role functioning, mental health. Surprisingly, in
line with the study of [20], the level of biomarkers re-
ported to be directly linked to physical status and pain
are not influencing social functioning, role-emotional,
levels of depression and anxiety [20]. In conclusion, the
outcome of our work was that, for the first time, we have
found a biomarkers combination which, in accordance
with literature, was able to produce reliable k-NN pre-
diction results. Thanks to this ML algorithm, we will be
able to correctly predict KOOS symptoms of a new
AKU patient just relying on clinical and lifestyle data.
Current study limitations and future perspective
There are several challenges in studying an ultra-rare
and complex disease like AKU, and specifically (i) the
paucity of specimens and available data, and (ii) the lack
of a standardized method able to objectively assess dis-
ease severity or response to treatment. For this reason
we developed ApreciseKUre database, aiming to collect
as many AKU patients’ data as possible, and to use QoL
scores to monitor patients’ clinical condition and health
status, although the database does not yet include ob-
jective disease severity findings (i.e. imaging, cardiac
valve or calcification, radiographic severity score, treat-
ment modalities, time to surgery, etc). We believe that
this study could be a starting point for a better investiga-
tion of the utility and reliability of QoL scores, which are
becoming increasingly popular, and their correlation to
biochemical and clinical biomarkers. For example, the
AKUSSI score, which incorporates into a single score
multiple clinically meaningful AKU outcomes, medical
photography imaging investigations and detailed ques-
tionnaires, performed poorly in the model based on the
selected biomarkers (AKUSSI joint pain RAE 0.37 and
AKUSSI spinal pain RAE 0.55). However, as shown in
Fig. 3, parameters like age, SAA, CHIT1, AOPP, RSSP,
BMI were the 6 variables with the highest importance
values. In literature, these 6 variables have been already
used as biomarkers for AKU. In fact, there is an intimate
connection between HGA and the ochronotic process,
SAA and amyloidosis, inflammation and oxidative stress
in AKU, as demonstrated by structural co-localization of
ochronotic pigment and SAA-amyloid and co-
localization of SAA with crucial cytoskeletal proteins in
AKU chondrocytes [20]. As described in [12], some
AKU patients, who underwent joint replacement surgery
Fig. 5 Surrogate Test Analysis. Comparison of performance based on RAE values, between k-NNs trained on surrogate data (red) and original
dataset (blue)
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and complained about articular disorders, arthropathy
and joint pain together with other co-morbidities,
showed pathological levels of SAA and AOPP above the
reference value. Moreover, serum concentration of SAA
[41, 42] and CHIT1 activity [43, 44] are markers of dis-
ease severity in several rheumatic conditions, and in [20]
was provided the evidence that AKU patients present
significantly high SAA and chitotriosidase activity in
comparison with controls. Some objective disease sever-
ity findings, such as cardiac valve calcification and
treatment modalities, are strictly linked with amyloid-
osis, inflammation and oxidative stress. For example, in
[11, 16, 17], SAA deposition was detected by immuno-
fluorescence technique in AKU aortic valve and it was
tested that low dose methotrexate can down-regulate in-
flammation and lower SAA production in AKU [20].
In a complex disease like AKU, also lifestyle parameters
like BMI are not neglectable. As shown in Table 2, SAA
and AOPP have a weak direct correlation with BMI (p-
value respectively 0.01 and 0.10), which in turn increases
with age. It has been previously shown that oxidative stress
increase with a rising BMI, as a consequence of an impaired
antioxidant status [20, 45] through various biochemical
mechanisms, such as superoxide generation from NADPH
oxidases, oxidative phosphorylation and glyceraldehyde
auto-oxidation [46]. Moreover, in line with [20], a positive
association was found between SAA and BMI, since in
obesity (where low-grade inflammation is found) adipose
tissue is the major source of SAA, which can be considered
an obesity-related inflammatory protein [47, 48].
Age is an important driving factor for the prediction of
QoL scores and it is a common observation that clinical
symptoms might worse with aging. In fact, as shown in
Table 2, CHIT1 and RSSP correlate with age (p-value 0.0
for both biomarkers). This is confirmed by the fact that
when age is removed from the set of six biomarkers (SAA,
CHIT1, AOPP, RSSP, BMI) able to predict QoL scores,
the k-NN RAE of KOOS symptoms jump to 0.31. Unfor-
tunately, it is not easy to gather data of very young pa-
tients, since people start showing AKU symptoms in their
30/40s, even if the dark discoloration of the urine is
present from birth. The systematic use of the Aprecise-
KUre database will increase the number of patients and
will allow us to develop an upgraded version of our algo-
rithm to include an adjustment for the age of the patients.
It is important to specify that this study was based on
baseline biochemical and clinical analysis, since the very
limited number of information regarding the longitu-
dinal changes, changes during the acute phase, medica-
tion effects, differences after joint replacement did not
produce robust statistical results. Being AKU a chronic
but not lethal disease, the future direction of our study
will aim at collecting more AKU follow-up patients’ data
before and after treatments, in order to evaluate the
effectiveness of different therapies. This will be an essen-
tial point for a typical precision medicine approach, in
which each patient is closely monitored over time and
several types of information are collected to understand
the uniqueness of each individual. This predictive system
will allow for the easy monitoring of AKU disease evolu-
tion and it will help clinicians in the selection of the
most appropriate treatment, and evaluate its efficacy by
observing the trend of QoL scores and biomarkers. In
summary, this cost-effective computational method will
be beneficial in supporting experimental and clinical
studies and, at the same time, will help patients by iden-
tifying the most promising treatments.
Conclusion
In conclusion, the combination of a ML to analyse and re-
interpret data available in the ApreciseKUre shows the po-
tential direct benefits for patient care and treatments,
highlighting the necessity of patient databases for rare dis-
eases, like ApreciseKUre. We believe this is not limited to
the study of AKU, but it represents a proof of principle
study that could be applied to other rare diseases, allowing
data management, analysis and interpretation.
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